Simulations Plus Inc. (SLP)
| Bid | 24.5 |
| Market Cap | 513.56M |
| Revenue (ttm) | 74.53M |
| Net Income (ttm) | 8.18M |
| EPS (ttm) | 0.4 |
| PE Ratio (ttm) | 63.9 |
| Forward PE | 26.9 |
| Analyst | Buy |
| Ask | 29 |
| Volume | 248,895 |
| Avg. Volume (20D) | 212,171 |
| Open | 24.37 |
| Previous Close | 24.68 |
| Day's Range | 24.00 - 25.97 |
| 52-Week Range | 24.00 - 51.22 |
| Beta | 0.89 |
About SLP
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus...
Analyst Forecast
According to 7 analyst ratings, the average rating for SLP stock is "Buy." The 12-month stock price forecast is $50, which is an increase of 95.62% from the latest price.
Stock Forecasts
1 month ago · businesswire.com
Simulations Plus to Participate in Upcoming Healthcare Investor ConferencesRESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance an...
2 months ago · businesswire.com
Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SLP highlighted its impact on the pharma industry through support of the development of a majority of the drugs approved by the U.S. FDA in 2024.
2 months ago · businesswire.com
Simulations Plus Supported Development of Every FDA-Approved Drug in 2024RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SLP highlighted its impact on the pharmaceutical industry through supporting the development of 100% of the drugs approved by the U.S. FDA in 2024.
2 months ago · businesswire.com
Simulations Plus Reports First Quarter Fiscal 2025 Financial ResultsRESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intel...